Payment overview · 2025
General Payments
$401.21
23 reported records · 11 companies
Healthcare provider profile · identity verified
Robert A Ludwick, MD
Allopathic & Osteopathic Physicians|General Practice · FITZGERALD, GA · NPI 1043300999
Verified facts
What the public records show
CMS Open Payments records show Robert A Ludwick, MD received $401.21 in general payments during 2025 across 23 reported records.
Ardelyx, Inc. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $66.14 | 16.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.82 | 15.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.43 | 14.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.78 | 10.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.69 | 7.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.67 | 7.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.50 | 7.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.39 | 7.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.65 | 4.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.56 | 4.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.58 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.21 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $66.14 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.39 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
108 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 708 | 197 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 618 | 100 |
| Potassium Chloride | Potassium Chloride | 527 | 121 |
| Omeprazole | Omeprazole | 523 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 147 |
| Montelukast Sodium | Montelukast Sodium | 462 | 105 |
| Metformin Hcl | Metformin Hcl | 458 | 120 |
| Gabapentin | Gabapentin | 385 | 116 |
| Losartan Potassium | Losartan Potassium | 384 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 95 |
| Lisinopril | Lisinopril | 351 | 104 |
| Alprazolam | Alprazolam | 343 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 66 |
| Tramadol Hcl | Tramadol Hcl | 331 | 81 |
| Famotidine | Famotidine | 314 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 293 | 59 |
| Furosemide | Furosemide | 291 | 74 |
| Meloxicam | Meloxicam | 274 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 61 |
| Trazodone Hcl | Trazodone Hcl | 260 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 40 |
| Glimepiride | Glimepiride | 213 | 52 |
| Simvastatin | Simvastatin | 202 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 197 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 57 |
| Eliquis | Apixaban | 186 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 65 |
| Carvedilol | Carvedilol | 166 | 48 |
| Allopurinol | Allopurinol | 161 | 37 |
| Jardiance | Empagliflozin | 145 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 20 |
| Spironolactone | Spironolactone | 128 | 34 |
| Lorazepam | Lorazepam | 125 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 37 |
| Mounjaro | Tirzepatide | 112 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 23 |
| Linzess | Linaclotide | 108 | 18 |
| Nifedipine Er | Nifedipine | 108 | 33 |
| Buspirone Hcl | Buspirone Hcl | 103 | 20 |
| Clonidine Hcl | Clonidine Hcl | 103 | 28 |
| Mirtazapine | Mirtazapine | 97 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 96 | 12 |
| Atenolol | Atenolol | 95 | 30 |
| Ozempic | Semaglutide | 90 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 21 |
| Donepezil Hcl | Donepezil Hcl | 83 | 18 |
| Meclizine Hcl | Meclizine Hcl | 82 | 30 |
| Sertraline Hcl | Sertraline Hcl | 82 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 80 | 20 |
| Ezetimibe | Ezetimibe | 80 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 71 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Amoxicillin | Amoxicillin | 67 | 53 |
| Carisoprodol | Carisoprodol | 65 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 25 |
| Memantine Hcl | Memantine Hcl | 65 | suppressed |
| Nystatin | Nystatin | 65 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 24 |
| Naproxen | Naproxen | 62 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Finasteride | Finasteride | 54 | suppressed |
| Fluconazole | Fluconazole | 54 | 23 |
| Lovastatin | Lovastatin | 53 | 17 |
| Prednisone | Prednisone | 53 | 29 |
| Brilinta | Ticagrelor | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 16 |
| Pregabalin | Pregabalin | 47 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 13 |
| Xarelto | Rivaroxaban | 46 | 15 |
| Glipizide | Glipizide | 45 | 14 |
| Hydrocortisone | Hydrocortisone | 45 | suppressed |
| Celecoxib | Celecoxib | 43 | 13 |
| Baclofen | Baclofen | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 22 |
| Topiramate | Topiramate | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 13 |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Azithromycin | Azithromycin | 30 | 27 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.21 · 23 records | Ardelyx, Inc. | AIRSUPRA, AREXVY, AUSTEDO XR, FANAPT, FARXIGA, IBSRELA, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error